Azabicycloalkyl Benzimidazolone Derivatives As a Novel Class of Potent Agonists at the 5-HT4 Receptor Positively Coupled to Adenylate Cyclase in Brain

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1991 Mar 1

PMID 1650917

Citations 16

Authors

A Dumuis

M Sebben

E MONFERINI

M Nicola

M Turconi

H Ladinsky

J Bockaert

Affiliations

Soon will be listed here.

Abstract

Recent experimental evidence indicates that central 5-HT4 receptors which are positively coupled to adenylate cyclase, are stimulated by a family of 2-methoxy-4-amino-5-chloro substituted benzamide derivatives. These compounds are also potent stimulants of the gastro-intestinal motility. In this study the ability of three azabicycloalkyl benzimidazolone derivatives, BIMU 1, BIMU 8, and DAU 6215 (structural formulas are given in the text), to stimulate cAMP formation in colliculi neurons in primary culture have been tested. Two of the compounds, BIMU 1 and BIMU 8, which show prokinetic activity in various animal models, were also good agonists at the 5-HT4 receptors, whereas DAU 6215, a drug devoid of prokinetic activity, was only a weak, partial agonist at 5-HT4 receptors. The rank order of their potencies as compared with those of 5-HT and cisapride was as follows: BIMU 8 = cisapride greater than 5-HT greater than BIMU 1 greater than DAU 6215. The efficacies of BIMU 8 and cisapride were comparable (133 +/- 9% and 124 +/- 8% of the maximal 5-HT efficacy, respectively), whereas BIMU 1 and DAU 6215 elicited, respectively, only 72 +/- 11% and 16 +/- 4% of the maximal 5-HT effect. The activities of the azabicycloalkyl benzimidazolone derivatives and 5-HT on cAMP formation were not additive and ICS 205-930 antagonized the stimulatory effect of these compounds with low potency (pKi = 6.1-6.4), further strengthening the notion of interaction with 5-HT4 receptors. In addition, cross desensitization between the effects of 5-HT and the azabicycloalkyl benzimidazolones on adenylate cyclase was noted, another argument in favor of an interaction of these drugs on 5-HT4 receptors.

Citing Articles

Anticholinesterase and Serotoninergic Evaluation of Benzimidazole-Carboxamides as Potential Multifunctional Agents for the Treatment of Alzheimer's Disease.

Belinskaia D, Voronina P, Krivorotov D, Jenkins R, Goncharov N Pharmaceutics. 2023; 15(8).

PMID: 37631373 PMC: 10459044. DOI: 10.3390/pharmaceutics15082159.

International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.

Barnes N, Ahern G, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S Pharmacol Rev. 2020; 73(1):310-520.

PMID: 33370241 PMC: 7770494. DOI: 10.1124/pr.118.015552.

5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice.

Liu M, Kuan Y, Wang J, Hen R, Gershon M J Neurosci. 2009; 29(31):9683-99.

PMID: 19657021 PMC: 2749879. DOI: 10.1523/JNEUROSCI.1145-09.2009.

BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse.

Lelong V, Lhonneur L, Dauphin F, Boulouard M Naunyn Schmiedebergs Arch Pharmacol. 2003; 367(6):621-8.

PMID: 12736770 DOI: 10.1007/s00210-003-0743-2.

Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists.

Candura S, Messori E, Franceschetti G, DAgostino G, Vicini D, Tagliani M Br J Pharmacol. 1996; 118(8):1965-70.

PMID: 8864530 PMC: 1909897. DOI: 10.1111/j.1476-5381.1996.tb15631.x.

References

Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J . A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol. 1988; 34(6):880-7. View

Dumuis A, Sebben M, Bockaert J . BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. Eur J Pharmacol. 1989; 162(2):381-4. DOI: 10.1016/0014-2999(89)90304-x. View

Turconi M, Nicola M, Quintero M, Maiocchi L, Micheletti R, Giraldo E . Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists. J Med Chem. 1990; 33(8):2101-8. DOI: 10.1021/jm00170a009. View

Dumuis A, Sebben M, Bockaert J . The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(4):403-10. DOI: 10.1007/BF00167041. View

Sanger G . Activation of a myenteric 5-hydroxytryptamine-like receptor by metoclopramide. J Pharm Pharmacol. 1987; 39(6):449-53. DOI: 10.1111/j.2042-7158.1987.tb03418.x. View

Dumuis A, Bouhelal R, Sebben M, Bockaert J . A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930. Eur J Pharmacol. 1988; 146(1):187-8. DOI: 10.1016/0014-2999(88)90503-1. View

Kilpatrick G, Jones B, Tyers M . Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature. 1987; 330(6150):746-8. DOI: 10.1038/330746a0. View

Craig D, Clarke D . Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor. J Pharmacol Exp Ther. 1990; 252(3):1378-86. View

Tonini M, Rizzi C, Manzo L, Onori L . Novel enteric 5-HT4 receptors and gastrointestinal prokinetic action. Pharmacol Res. 1991; 24(1):5-14. DOI: 10.1016/1043-6618(91)90059-7. View

10.

Sanger G . Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. Br J Pharmacol. 1987; 91(1):77-87. PMC: 1853491. DOI: 10.1111/j.1476-5381.1987.tb08985.x. View

11.

Clarke D, Craig D, Fozard J . The 5-HT4 receptor: naughty, but nice. Trends Pharmacol Sci. 1989; 10(10):385-6. DOI: 10.1016/0165-6147(89)90177-6. View

12.

Weiss S, Pin J, Sebben M, Kemp D, Sladeczek F, Gabrion J . Synaptogenesis of cultured striatal neurons in serum-free medium: a morphological and biochemical study. Proc Natl Acad Sci U S A. 1986; 83(7):2238-42. PMC: 323267. DOI: 10.1073/pnas.83.7.2238. View

13.

Buchheit K, Engel G, Mutschler E, Richardson B . Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol. 1985; 329(1):36-41. DOI: 10.1007/BF00695189. View

14.

Peroutka S . 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci. 1988; 11(11):496-500. DOI: 10.1016/0166-2236(88)90011-2. View

15.

Bradley P, Engel G, Feniuk W, Fozard J, Humphrey P, Middlemiss D . Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986; 25(6):563-76. DOI: 10.1016/0028-3908(86)90207-8. View

16.

Weiss S, Sebben M, Garcia-Sainz J, Bockaert J . D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture. Mol Pharmacol. 1985; 27(6):595-9. View

17.

Bockaert J, Sebben M, Dumuis A . Pharmacological characterization of 5-hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol Pharmacol. 1990; 37(3):408-11. View

18.

Sanger G . Three different ways in which 5-hydroxytryptamine can affect cholinergic activity in guinea-pig isolated ileum. J Pharm Pharmacol. 1985; 37(8):584-6. DOI: 10.1111/j.2042-7158.1985.tb03076.x. View

19.

Schmidt M, IMBS J, Schwartz J . The vascular dopamine receptor : a review. J Pharmacol. 1981; 12(4):355-82. View

20.

Richardson B, Engel G, Donatsch P, Stadler P . Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature. 1985; 316(6024):126-31. DOI: 10.1038/316126a0. View